126 related articles for article (PubMed ID: 19106505)
1. [Anti-VEGF therapy for peritoneal dissemination model of gastric cancer considering of pharmacokinetics].
Yagi Y; Fushida S; Fujita H; Kinami S; Ninomiya I; Fujimura T; Kayahara M; Ohta T; Yashiro M; Hirakawa K
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2005-8. PubMed ID: 19106505
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Yagi Y; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Fujita H; Ninomiya I; Fujimura T; Kayahara M; Kinuya S; Yashiro M; Hirakawa K; Ohta T
Cancer Chemother Pharmacol; 2010 Sep; 66(4):745-53. PubMed ID: 20033809
[TBL] [Abstract][Full Text] [Related]
3. Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
Ninomiya S; Inomata M; Tajima M; Ali AT; Ueda Y; Shiraishi N; Kitano S
J Surg Res; 2009 Jun; 154(2):196-202. PubMed ID: 19329124
[TBL] [Abstract][Full Text] [Related]
4. [The use of bevacizumab in refractory peritoneal dissemination of gastric cancer with malignant ascites-two case reports].
Kinoshita J; Fushida S; Makino I; Nakamura K; Oyama K; Nakagawara H; Fujita H; Tajima H; Takamura H; Ninomiya I; Kitagawa H; Tani T; Miyamoto M; Fujimura T; Ota T
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2360-2. PubMed ID: 22202382
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis.
Tokuyama J; Kubota T; Saikawa Y; Yoshida M; Furukawa T; Otani Y; Kumai K; Kitajima M
Anticancer Res; 2005; 25(1A):17-22. PubMed ID: 15816514
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
Li H; Adachi Y; Yamamoto H; Min Y; Ohashi H; Ii M; Arimura Y; Endo T; Lee CT; Carbone DP; Imai K; Shinomura Y
Cancer; 2011 Jul; 117(14):3135-47. PubMed ID: 21264842
[TBL] [Abstract][Full Text] [Related]
7. Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as "soil" for peritoneal dissemination.
Yashiro M; Chung YS; Nishimura S; Inoue T; Sowa M
Cancer; 1996 Apr; 77(8 Suppl):1668-75. PubMed ID: 8608560
[TBL] [Abstract][Full Text] [Related]
8. [Effect of anti-vascular endothelial growth factor antibody on the progression of human gastric cancer orthotopic xenotransplanted into nude mice].
Tao H; Lin Y; Yin H; Yao M
Zhonghua Wai Ke Za Zhi; 1999 Apr; 37(4):248-50. PubMed ID: 11829834
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
10. ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma.
Tanaka H; Yashiro M; Sunami T; Sakate Y; Kosaka K; Hirakawa K
Clin Cancer Res; 2004 Jul; 10(14):4885-92. PubMed ID: 15269165
[TBL] [Abstract][Full Text] [Related]
11. Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model.
Imaizumi T; Aoyagi K; Miyagi M; Shirouzu K
Surg Today; 2010 Sep; 40(9):851-7. PubMed ID: 20740349
[TBL] [Abstract][Full Text] [Related]
12. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
[TBL] [Abstract][Full Text] [Related]
13. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: the first step before intraperitoneal anti-vascular endothelial growth factor treatment?
Passot G; Bakrin N; Garnier L; Roux A; Vaudoyer D; Wallet F; Gilly FN; Glehen O; Cotte E
Eur J Cancer; 2014 Mar; 50(4):722-30. PubMed ID: 24295636
[TBL] [Abstract][Full Text] [Related]
15. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
16. [Intraoperative and postoperative intra-peritoneal administration of peptide PIII inhibits peritoneal metastasis of gastric cancer].
Bai FH; Yang L; Ji Q; Zhang YQ; Liu ZX; Wang ZZ; Yan L; Wang JB; Jin HF; Li TT
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(46):3260-3. PubMed ID: 17313805
[TBL] [Abstract][Full Text] [Related]
17. Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer.
Zhang C; Awasthi N; Schwarz MA; Schwarz RE
J Surg Res; 2013 Jun; 182(2):227-34. PubMed ID: 23201270
[TBL] [Abstract][Full Text] [Related]
18. ZnPPIX inhibits peritoneal metastasis of gastric cancer via its antiangiogenic activity.
Shang FT; Hui LL; An XS; Zhang XC; Guo SG; Kui Z
Biomed Pharmacother; 2015 Apr; 71():240-6. PubMed ID: 25960243
[TBL] [Abstract][Full Text] [Related]
19. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
20. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
Deguchi T; Shikano T; Kasuya H; Nawa A; Fujiwara S; Takeda S; Gewen T; Sahin TT; Yamada S; Kanzaki A; Yamamura K; Fujii T; Sugimoto H; Nomoto S; Fukuda S; Nishikawa Y; Kodera Y; Nakao A
Hepatogastroenterology; 2012 Sep; 59(118):1844-50. PubMed ID: 22172413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
